The final rule amends the regulations
for filing an application to market a biological product under
section 601.2 to eliminate the references to establishment licenses
(ELA) and product licenses (PLA) for all products regulated under
the PHS Act. The final rule will require manufacturers to file a
single biologics license application (BLA), rather than an ELA and
PLA to market a biological product.